Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is December - November.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 3, 2026	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021
Market Capitalization	1,562	1,792	1,566	302	584	1,286
Market Cap Growth	17.16%	14.43%	419.13%	-48.35%	-54.57%	-22.36%
Enterprise Value	1,089	1,420	1,136	41	184	942
Last Close Price	15.81	17.68	22.11	6.22	12.39	28.82
PS Ratio	19.36	21.34	28.71	3.92	15.12	43.22
PB Ratio	2.99	3.33	2.97	1.51	1.92	3.76
P/TBV Ratio	3.02	3.33	2.97	1.51	1.92	3.76
EV/Sales Ratio	12.96	16.91	20.82	0.53	4.76	31.66
Debt / Equity Ratio	0.10	0.10	0.05	0.15	0.04	0.04
Net Debt / Equity Ratio	-1.00	-1.00	-1.10	-1.32	-1.19	-1.23
Net Debt / EBITDA Ratio	1.94	1.94	2.84	1.78	2.01	3.62
Net Debt / FCF Ratio	2.04	2.04	3.20	2.95	2.10	4.66
Asset Turnover	0.12	0.12	0.11	0.20	0.09	0.07
Quick Ratio	6.87	6.87	6.38	3.32	4.39	4.57
Current Ratio	7.02	7.02	6.46	3.40	4.51	4.70
Return on Equity (ROE)	-49.63%	-49.63%	-53.22%	-57.10%	-55.84%	-37.05%
Return on Assets (ROA)	-26.30%	-26.30%	-25.98%	-25.10%	-25.72%	-16.88%
Return on Capital Employed (ROCE)	-47.50%	-47.50%	-37.10%	-57.70%	-53.10%	-28.70%
Earnings Yield	-16.26%	-14.76%	-12.36%	-47.71%	-30.88%	-9.12%
FCF Yield	-16.20%	-14.70%	-11.61%	-29.75%	-29.45%	-7.00%
Buyback Yield / Dilution	-29.12%	-29.12%	-23.52%	-11.79%	-13.32%	-173.68%

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q